Description: This study quantifies the range of intercompany variability in mortality. Mean actual-to-expected (A/E) ratios based on amount were calculated in each quintile for every combination of six key variables.

Description: After a sustained period of mortality improvement, U.S. population mortality improvement has stagnated in recent years. The presenters will discuss mortality improvement trends in the U.S. population and the causes of death contributing to these trends. U.S. population cause of death trends will be analyzed and compared to trends in the insured population. Mortality rates for major causes of death will be compared between the U.S. population and the insured population. In addition, assumption setting for both older age and later duration mortality as well as mortality improvement will be covered.

Description: Summarizes the results of a follow-up survey of a panel of experts on COVID-19 to see how views on the disease’s impact on future U.S. mortality may have changed.

Description: U.S. population death statistics and trends often occupy COVID-19 briefings and daily headlines. There are also publicly available mortality data sources for actuaries and others to perform their own analysis. Yet industry studies examining the impact of COVID-19 on insured populations are in their infancy. In this webcast, presenters will provide insights into how the life insured population is faring during COVID-19 by discussing the findings from two recent SOA research initiatives. LIMRA, RGA Reinsurance, the Society of Actuaries and TAI have collaborated on an effort to analyze the impact of COVID-19 on the individual life insurance industry’s mortality experience. Additionally, the SOA has surveyed insurers to gather a high-level view of U.S. Group Term Life Insurance mortality results during the COVID-19 pandemic and comparing them to pre-pandemic mortality levels.

Description: An analysis of US population mortality trends and the impact of COVID.

Description: This paper compares two mortality projection models – the latest version of the CMI Mortality Projections Model and the latest version of MIM-2021.Both models were applied to data for England & Wales and the US, and the results were compared.

Description: Discuss changes in group life waiver of premium claim recovery and mortality experience since the 2005 table was released, the development of the 2023 table, and the new statutory valuation standard approved by the National Association of Insurance Commissioners (NAIC).

Description: Are you searching for an overview of the SOA Research Institute's Mortality & Longevity Strategic Research Program? Join us for an introduction into studies focusing on the historical U.S. population and insured mortality trends. Two research projects are observed in this webcast, one examining the impact of COVID-19 on mental illness and the impact of mental illness on U.S. Mortality & Longevity. The second study looks into the Group Life COVID-19 Mortality Survey and the high level view of U.S. group term life insurance mortality results during the pandemic. Come explore the research goals and the future for the Mortality & Longevity Strategic Program.

Description: The most recent U.S. population data released by the Centers for Disease Control and Prevention (CDC) and from the U.S. Census at year-end 2021 includes the first ten months of the COVID-19 pandemic in the U.S. While we know the pandemic has had significant impacts on both the U.S. population and insured population mortality, we also see increased mortality due to many other non-COVID causes of death. Where are the biggest changes and what does this non-COVID excess mortality mean over the next few years? Take part as an expert panel hosts an interactive discussion to examine data from general population as well as from both individual life and group life experience studies to explore how these changes might spur innovation in underwriting, assumption setting and pricing.

Description: Future mortality improvement has been a common assumption in life insurance and annuity pricing and forecasting for many years. However, experience over the last decade suggests this might be an assumption that merits reconsideration in the United States. This article will take a closer look at factors that impact mortality improvement trends and discuss why insurers may want to reevaluate product designs to better manage the associated mortality risk. We then introduce a product idea with this in mind, where premiums are based on a life expectancy index and insurers share the risk (and opportunity) or mortality improvement with policyholders.